|
Topic 371 - Phase I SBIR Contract - Valudation and Optimization of RP-185 as Adjuvant to Exploit the Immune Response Generated by Radiation
|
261201800023C
|
$299,847
|
-, -
|
RIPTIDE BIOSCIENCE, INC.
|
|
Modeling bladder cancer pathogenesis and tumor evolution
|
1P01CA221757-01A1
|
$1,765,498
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S1
|
$120,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S2
|
$60,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S3
|
$118,652
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-43S4
|
$199,541
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
5P30CA013696-43
|
$3,792,720
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Molecular mechanisms of prostate cancer metastasis
|
5R01CA183929-03
|
$366,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Role of NFxB/HIF2a axis in renal cell carcinoma progression
|
5K08CA178168-05
|
$175,163
|
ABEL, E
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
Mechanisms Underlying Functional Programs of Tumor-Associated Macrophages
|
5R01CA172105-03
|
$401,456
|
ABRAMS, SCOTT
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-09
|
$461,999
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-10
|
$461,172
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Center for Multiple Myeloma Nanotherapy
|
3U54CA199092-03S1
|
$29,864
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Center for Multiple Myeloma Nanotherapy
|
5U54CA199092-03
|
$2,224,884
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Center for Multiple Myeloma Nanotherapy
|
5U54CA199092-04
|
$2,184,301
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
|
5U54CA163069-07
|
$1,414,315
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
|
5U54CA163069-08
|
$1,347,488
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
Plumbagin in Combination with Vemurafenib for BRAF-mutant Melanoma
|
1R03CA212798-01
|
$74,250
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Novel Combinatorial Therapeutic Approach for Prostate Cancer
|
1R03CA219336-01
|
$74,250
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Plumbagin in Combination with Vemurafenib for BRAF-mutant Melanoma
|
5R03CA212798-02
|
$74,250
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Novel Combinatorial Therapeutic Approach for Prostate Cancer
|
5R03CA219336-02
|
$74,250
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Platelets promote growth of ovarian cancer
|
5R01CA177909-05
|
$332,000
|
AFSHAR-KHARGHAN, VAHID
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
ANALYSIS AND THERAPEUTIC TARGETING OF BREAST CANCER DISSEMINATED TUMOR CELLS
|
5R01CA172623-05
|
$384,803
|
AFT, REBECCA
|
WASHINGTON UNIVERSITY
|
|
High Throughput Mechanical Modulatory Assay for Breast Cancer Drug Testing
|
5R21CA210126-02
|
$207,928
|
AGAH, MASOUD
|
VIRGINIA POLYTECHNIC INST AND ST UNIV
|
|
Analysis of HCC CTC Phenotype for Liver Transplant Candidate Selection
|
1R21CA216807-01A1
|
$203,254
|
AGOPIAN, VATCHE
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Epigenetic and microenvironmental regulation of dormant disseminated cancer
|
1R01CA218024-01
|
$445,511
|
AGUIRRE-GHISO, JULIO
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Functional Determinants of Metastatic Dormancy
|
5R01CA109182-14
|
$428,739
|
AGUIRRE-GHISO, JULIO
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-02
|
$474,276
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-03
|
$470,573
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Post-translational control of cancer cell stress response and metastasis
|
5R01CA202027-02
|
$459,505
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Title: Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA in Combination with Immune Checkpoint Blockade
|
1R43CA228721-01
|
$299,607
|
AKPORIAYE, EMMANUEL
|
VEANA THERAPEUTICS, LLC
|
|
Development of novel gallium-68 bisphosphonate for imaging bone metastases in prostate cancer
|
1R43CA221580-01
|
$225,000
|
ALEXOFF, DAVID
|
FIVE ELEVEN PHARMA, INC.
|
|
Single-Cell Measurement of Lipid Signaling in Colorectal Cancer
|
5R01CA177993-04
|
$584,480
|
ALLBRITTON, NANCY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Single-Cell Measurement of Lipid Signaling in Colorectal Cancer
|
5R01CA177993-05
|
$575,397
|
ALLBRITTON, NANCY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Multicellular Cancer Cell Cluster Extravasation through Angiopellosis
|
1F31CA217153-01A1
|
$34,660
|
ALLEN, TYLER
|
NORTH CAROLINA STATE UNIVERSITY RALEIGH
|
|
Dosage-Dependent Hedgehog Signaling in Pancreatic Cancer
|
5R01CA198074-03
|
$378,171
|
ALLEN, BENJAMIN
|
UNIVERSITY OF MICHIGAN
|
|
Dosage-Dependent Hedgehog Signaling in Pancreatic Cancer
|
5R01CA198074-04
|
$378,171
|
ALLEN, BENJAMIN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Targeting Tumor Initiating Cell in Undifferentiated Pleomorphic Sarcoma
|
5R01CA183811-04
|
$435,560
|
ALMAN, BENJAMIN
|
DUKE UNIVERSITY
|
|
Targeting Tumor Initiating Cell in Undifferentiated Pleomorphic Sarcoma
|
5R01CA183811-05
|
$435,560
|
ALMAN, BENJAMIN
|
DUKE UNIVERSITY
|
|
Tumor Plasticity
|
1R35CA220446-01
|
$900,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-48S1
|
$142,498
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S2
|
$200,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Control of Apoptosis in Cancer by Survivin
|
3R01CA078810-19S1
|
$228,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Novel Molecular Therapies of Prostate Cancer
|
5P01CA140043-08
|
$1,239,835
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-48
|
$2,645,581
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-49
|
$2,645,581
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Control of Apoptosis in Cancer by Survivin
|
5R01CA078810-20
|
$380,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
The Role of LSD1 in the Evolution of Castration Resistant Prostate Cancer
|
5R01CA178610-04
|
$316,934
|
ALUMKAL, JOSHI
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
Par-4 Regulation and Function in Breast Cancer Dormancy and Recurrence
|
3R01CA208042-03S1
|
$223,893
|
ALVAREZ, JAMES
|
DUKE UNIVERSITY
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|